有关创新途径下基于细胞的干预措施的临床转化的问题。
Questions concerning the clinical translation of cell-based interventions under an innovation pathway.
机构信息
Berman Institute of Bioethics, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
J Law Med Ethics. 2012 Winter;40(4):945-50. doi: 10.1111/j.1748-720X.2012.00723.x.
Abstract
Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.
摘要
基于干细胞的创新是临床转化的一种途径，与临床研究和医疗治疗形成对比。本文在回顾最近发布的负责任创新指南后，探讨了使用该途径的潜在益处和危害，以及该途径所面临的实际障碍和概念性问题。
Zotero 插件